Jacobson Pharma Corporation Limited provided earnings guidance for the six months ended 30 September 2019. The Group is expected to record an increase of over 30% in the consolidated profit attributable to shareholders of the Company for the six months ended 30 September 2019 as compared to that for the six months ended 30 September 2018. The expected increase is mainly attributable to a steady growth of the Group's generic drug business augmented with the sales revenue generated from newly in-licensed products, in addition to an uplifted sales performance on proprietary medicines. Operating leverage and financial savings derived from cost control measures also helped contribute to the expected increase in earnings. Fair value gain on redemption of convertible notes and investment properties of the Group is also expected to contribute, although to a lesser extent, to the increase in consolidated profit attributable to shareholders of the Company.